Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
4.120
+0.040 (0.98%)
Nov 20, 2024, 4:00 PM EST - Market closed
Kyverna Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 7.03 | 5.66 |
| Revenue Growth (YoY) | - | - | 24.20% | - |
| Cost of Revenue | 96.15 | 49.92 | 28.4 | 25.85 |
| Gross Profit | -96.15 | -49.92 | -21.38 | -20.2 |
| Selling, General & Admin | 26.79 | 12.48 | 8.01 | 6.15 |
| Operating Expenses | 26.79 | 12.48 | 8.01 | 6.15 |
| Operating Income | -122.94 | -62.41 | -29.38 | -26.35 |
| Interest Expense | -0.16 | -0.19 | -0.07 | -0 |
| Interest & Investment Income | 12.57 | 2.28 | 0.57 | 0 |
| Other Non Operating Income (Expenses) | -0.13 | -0.06 | -0.01 | -0 |
| Pretax Income | -110.66 | -60.37 | -28.89 | -26.35 |
| Net Income | -110.66 | -60.37 | -28.89 | -26.35 |
| Net Income to Common | -110.66 | -60.37 | -28.89 | -26.35 |
| Shares Outstanding (Basic) | 28 | 1 | 0 | 0 |
| Shares Outstanding (Diluted) | 28 | 1 | 0 | 0 |
| Shares Change (YoY) | 5987.19% | 47.89% | 71.30% | - |
| EPS (Basic) | -3.99 | -89.61 | -63.43 | -99.10 |
| EPS (Diluted) | -3.99 | -89.61 | -63.43 | -99.10 |
| Free Cash Flow | -97.76 | -53.03 | -36.88 | -23.44 |
| Free Cash Flow Per Share | -3.53 | -78.73 | -80.97 | -88.17 |
| Operating Margin | - | - | -418.28% | -465.81% |
| Profit Margin | - | - | -411.29% | -465.88% |
| Free Cash Flow Margin | - | - | -525.00% | -414.50% |
| EBITDA | -121.74 | -61.54 | -28.61 | -25.76 |
| D&A For EBITDA | 1.19 | 0.87 | 0.78 | 0.59 |
| EBIT | -122.94 | -62.41 | -29.38 | -26.35 |
Source: S&P Capital IQ. Standard template.
Financial Sources.